Lisanti Capital Growth LLC increased its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 143.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 96,935 shares of the company's stock after purchasing an additional 57,090 shares during the period. Lisanti Capital Growth LLC owned approximately 0.25% of Tarsus Pharmaceuticals worth $5,367,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also added to or reduced their stakes in the company. R Squared Ltd acquired a new stake in Tarsus Pharmaceuticals during the 4th quarter worth approximately $53,000. FMR LLC increased its stake in Tarsus Pharmaceuticals by 236.6% during the 3rd quarter. FMR LLC now owns 5,032 shares of the company's stock worth $166,000 after acquiring an additional 3,537 shares during the period. Victory Capital Management Inc. bought a new position in Tarsus Pharmaceuticals during the 4th quarter worth $223,000. Oppenheimer & Co. Inc. bought a new position in Tarsus Pharmaceuticals during the 4th quarter worth $227,000. Finally, Baader Bank Aktiengesellschaft bought a new position in Tarsus Pharmaceuticals during the 4th quarter worth $249,000. 90.01% of the stock is owned by institutional investors and hedge funds.
Shares of TARS opened at $43.57 on Friday. Tarsus Pharmaceuticals, Inc. has a 52-week low of $20.08 and a 52-week high of $57.28. The business's fifty day moving average is $50.14 and its 200-day moving average is $43.61. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The firm has a market cap of $1.67 billion, a price-to-earnings ratio of -11.44 and a beta of 1.05.
Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The company had revenue of $66.41 million for the quarter, compared to analyst estimates of $58.80 million. Equities analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.
A number of research firms have commented on TARS. Guggenheim restated a "buy" rating and set a $78.00 price objective (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday, February 24th. Oppenheimer raised their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 22nd. Jefferies Financial Group raised their price objective on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a research note on Thursday. Barclays lowered their price objective on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. Finally, HC Wainwright restated a "buy" rating and set a $73.00 price objective on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Tarsus Pharmaceuticals presently has a consensus rating of "Buy" and an average target price of $63.67.
Check Out Our Latest Research Report on TARS
Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Tarsus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tarsus Pharmaceuticals wasn't on the list.
While Tarsus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.